BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem Cells for Therapeutic Applications
09 Maio 2023 - 8:00AM
BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and
cell-derived therapeutics for the treatment of cardiovascular and
pulmonary diseases, today announces that the United States Patent
Office has granted Patent Number 11,642,377: titled, “ Bone Marrow
Derived Neurokinin-1 Receptor Positive (NK1R+) Mesenchymal Stem
Cells for Therapeutic Applications”, with a patent term that will
expire in 2039.
The patent specification details methods for selecting and
expanding NK1R+ Mesenchymal Stem Cells (MSC) and their use to treat
a number of diseases. The first allowed claim protects using these
cells to treat cardiovascular disease, pain, rheumatoid arthritis,
diabetes, stroke, asthma, pulmonary fibrosis, and aging. There are
seventeen additional claims allowed in this patent issuance.
“This has potential to be a breakthrough in mesenchymal stem
cell therapeutic development,” said Peter Altman, PhD, BioCardia
President and CEO. “Our team’s effort and understanding of disease
and injury led us to recognize that Substance P (SP) is the first
responder neuropeptide in defense, stress, repair, and survival
systems. We believe that how stem cells respond to SP is a critical
mechanism to injury and inflammation. As Neurokinin-1 (NK1) is the
primary receptor for SP on the surface of many cells, we explored
whether we could select mesenchymal stem cells expressing the
receptor and then expand them to clinically meaningful dosage
levels. With this patent issued today, BioCardia now holds rights
in the United States to a compelling therapeutic approach that has
promise to treat a wide range of diseases. We will be looking to
partner development in areas beyond our current cardiopulmonary
focus.”
About Biocardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is
developing cellular and cell-derived therapeutics for the treatment
of cardiovascular and pulmonary disease. CardiAMP™ autologous and
NK1R+ allogeneic cell therapies are the Company’s biotherapeutic
platforms that enable four product candidates in development. The
CardiAMP Cell Therapy Heart Failure Trial investigational product
has been granted Breakthrough designation by the FDA, has CMS
reimbursement, and is supported financially by the Maryland Stem
Cell Research Fund. The CardiAMP Chronic Myocardial Ischemia Trial
also has CMS Reimbursement. The Company's current products
include the Helix™ Transendocardial Biotherapeutic Delivery System,
which it partners selectively with other biotherapeutic companies
requiring local delivery to the heart. For more information
visit: www.BioCardia.com.
Forward Looking Statements:
This press release contains forward-looking statements that are
subject to many risks and uncertainties. Forward-looking statements
include, among other things, references to development and
importance of NK1R+ expanded MSC, our statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations. Such risks and uncertainties include, among others,
the inherent uncertainties associated with developing new products
or technologies, regulatory approvals, unexpected expenditures, the
ability to raise the additional funding needed to continue to
pursue BioCardia’s business and product development plans, the
ability to enter into licensing and partnering arrangements, and
overall market conditions. These forward-looking statements
are made as of the date of this press release, and BioCardia
assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,”
“might,” “will,” “should,” “approximately” or other words that
convey the uncertainty of future events or outcomes to identify
these forward-looking statements. Although we believe that we have
a reasonable basis for each forward-looking statement contained
herein, we caution you that forward-looking statements are not
guarantees of future performance and that our actual results may
differ materially from the forward-looking statements contained in
this press release. As a result of these factors, we cannot assure
you that the forward-looking statements in this press release will
prove to be accurate. Additional factors that could materially
affect actual results can be found in BioCardia’s Form 10-K filed
with the Securities and Exchange Commission on March 29, 2023,
under the caption titled “Risk Factors.” BioCardia expressly
disclaims any intent or obligation to update these forward-looking
statements, except as required by law.
Media Contact: Anne Laluc,
MarketingEmail: alaluc@BioCardia.com Phone:
650-226-0120
Investor Contact: David McClung, Chief
Financial OfficerEmail: investors@BioCardia.com Phone:
650-226-0120
BioCardia (NASDAQ:BCDA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
BioCardia (NASDAQ:BCDA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024